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One sentence Summary: A stringent filtering strategy applied to 751 ALS exomes 
identified p.D40G and other mutations in ANXA11 that produced cytoplasmic 
aggregates in patient spinal cord and in-vitro and disrupted calcyclin binding.    
 
Abstract: 
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder. We 
screened 751 familial ALS exomes and identified 6 novel, or extremely rare, ANXA11 
mutations in 13 individuals.  A novel p.D40G mutation was absent from 70,000 
control exomes; segregated with disease in two kindreds, was present in another two 
unrelated cases (p=0.0102), and all carriers shared a common founder haplotype.  
Annexin A11-positive aggregates were abundant in spinal motor neurons and 
hippocampal axons in a p.D40G patient. Transfected cells expressing p.D40G and 
other N-terminal mutations had altered calcyclin binding while a p.R235Q mutant 
formed insoluble aggregates. ANXA11 mutations accounted for ~1% of familial and 
~1.7% of apparent sporadic cases in our cohort. Mutations in ANXA11 highlight the 
role of defective cellular trafficking in the pathogenesis of ALS. 
 
Introduction 
Gene hunting in rare Mendelian disorders has been transformed by exome 
sequencing. This approach is particularly attractive for late-onset autosomal 
dominant syndromes with short disease durations, such as Amyotrophic Lateral 
Sclerosis (ALS) in which DNA from multiple affected individuals in the same kindred 
are rare. ALS has a life-time risk of 1 in 400 and is characterized by degeneration of 
brain and spinal cord motor neurons resulting in progressive paralysis and death 
within an average of 3 years [1]. 10% of cases are familial (FALS) and a causative 
gene mutation can be identified in ~60% of European kindreds [2]. Mutations in the 
same genes account for ~10% of sporadic ALS cases (SALS) reflecting incomplete 
penetrance. Non-synonymous mutations in SOD1, TARDBP, FUS and an intronic 
hexanucleotide repeat expansion in C9orf72 together account for ~20% of ALS 
cases and other genes for ~1-3% [3, 4]. Whole Exome and/or Genome Sequencing 
(WES/WGS) has identified nine ALS genes by either shared variant segregation 
analysis in ALS kindreds (VCP, PFN1, MATR3, CHCHD10, CCNF) or rare variant 
burden analysis (TUBA4A, TBK1, NEK1, C21orf2) [5-15]. Here we analysed FALS 
exomes and identified a novel non-synonymous founder mutation in ANXA11 that is 
present in all affected family members tested and is also found in multiple unrelated 
index cases. Annexin A11 is a widely expressed, calcium-dependent phospholipid-
binding protein (505AA, 56kDa) that belongs to the larger human Annexin family of 
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12 members [16]. Each family member has four highly conserved annexin domains, 
many of which can complex a calcium ion facilitating binding to anionic cell 
membranes. Unique to the annexin family, Annexin A11 has the longest N-terminus 
(~196 amino acids) that is hydrophobic, disordered and binds several interacting 
partners: the most characterized being calcyclin (encoded by S100A6) [17]. In regard 
to involvement with disease, Annexin A11 is associated with autoimmune disorders 
such as systemic lupus erythematosus and case-control studies have found a 
genetic association of the R230C single nucleotide polymorphism (SNP) with 
sarcoidosis [18, 19]. Additionally, enhanced Annexin A11 expression is also found in 
breast cancer and other acquired malignancies [18]. Here we present a new role for 
Annexin A11 in a rare, neurodegenerative Mendelian disorder as evidenced by novel 
mutations that cause Amyotrophic Lateral Sclerosis (ALS).  
 
Results 
(i) Exome sequencing, filtering and gene identification  
From our cohort of 751 European FALS exomes (negative for C9orf72 GGGGCC 
expansions) we obtained exome data for two or more affected relatives from only 50 
families (average=2.14 individuals per family), highlighting the difficulty in accessing 
DNA from extended kindreds for this late onset disorder. Families ranged from a 
simple pair of siblings (sharing an estimated 50% of their variants) to an index case, 
parent and a second cousin (sharing an estimated 1.5% of their variants). On 
average 84% (range=58-97%) of the protein coding bases contained in Refseq 
transcripts were sequenced in all family members to a depth of >=10 reads, a cut-off 
threshold in line with that used by the Exome Aggregation Consortium (ExAC) for 
defining high quality variants [20]. Our filtering strategy was to detect novel, high 
quality, coding and splicing variants that are absent from 1000genomes, UK10K, 
EVS and ExAC (n>72,000). This produced an average of ~10 candidates per family 
(range=0-27) (Supplementary Table 1). As proof of principle the analysis identified 
mutations shared in single kindreds from several known ALS genes, including SOD1, 
TARDBP, FUS, DCTN1 and TUBA4A [9, 21-24]. It was immediately apparent that 
only two variants appeared in the list of candidates for more than one family; the well 
characterized pathogenic M337V mutation in TARDBP [25] was found in two North 
American families, and a novel p.D40G variant in ANXA11 (Refseq NM_145869) was 
found in two British families (an uncle/niece pair, and two cousins). The full list of 
candidate variants found in both UK ANXA11 p.D40G families are listed in 
Supplementary Table 2. One additional Italian proband from the extended exome 
FALS cohort also carried the same ANXA11 D40G variant. 
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We then extended the analysis to include 694 unrelated European FALS probands 
(including only the 50 probands from our multiplex families) and sought novel protein-
changing variants that were shared by three or more probands. This approach also 
identified ANXA11 D40G, and the following well-characterised pathogenic ALS 
mutations: 10x SOD1 I114T [26], 6x TARDBP A382T [22], 5x SOD1 A5V [27] 4x 
FUS R521C [23], 3x TARDBP M337V, 3x SOD1 G94D [28], 3x FUS P525L [29]. 
We then Sanger sequenced the coding exons of ANXA11 in a separate set of 180 
British apparent SALS cases and identified one further heterozygous p.D40G carrier, 
bringing the total number to four out of a combined cohort of 874 probands.  
As the two p.D40G UK families were underpowered to conduct a linkage analysis 
(Simulated LOD score of 0.63 using MERLIN [30]) we sought an alternate method to 
ascertain the significance of the p.D40G mutation. It is possible that a variant could 
be present 4 times in a sample of 874 cases and absent from 72,000 other 
individuals yet still be unrelated to disease. We therefore tested the null hypothesis: 
that any equal sized cohort of Europeans could also contain a novel variant shared 
by at least 4 people. We achieved this by running simulation studies using the 
aggregated variant call counts from the Non-Finnish European (NFE) subset of the 
ExAC database (n=33,370). In brief, all ExAC NFE variants were randomly 
distributed across 33,370 simulated individuals and random cohorts of 874 people 
extracted. The cohort was deemed to have 'passed' if it contained at least one 
protein-changing variant found 4 or more times within the cohort, but absent from the 
remainder of ExAC, UK10K, EVS, and 1000genomes. After 250,000 iterations, only 
2,550 simulated cohorts contained such a variant, which demonstrates that the 
presence of the D40G variant is statistically significant (p=0.0102). Although not 
population-matched to our cohort, we consider ExAC to be suitable for this purpose 
as it contains a high proportion of Swedes who are on average more genetically 
homogeneous than UK individuals (Supplementary Table 3) [31]. Therefore ExAC 
would be expected to produce more shared non-pathogenic variants than our cohort, 
and so we expect this estimate of significance to be a conservative one. In 
conjunction with the family-based study the simulation analysis provides additional 
evidence that the ANXA11 D40G mutation is associated with ALS. 
 
(ii) The D40G mutation has a common European founder 
Sanger sequencing of DNA from 17 family members across the two multi-
generational British kindreds confirmed the presence of the p.D40G mutation in all 
four affected individuals identified from the exome capture data (Figs 1A-B). Four 
unaffected individuals also carried the mutation, but incomplete penetrance of ALS 
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mutations is well recognized and three of these were in their forties, whilst the 
average age of disease onset in ANXA11 p.D40G affected carriers is 72 years of 
age. DNA was available from five British p.D40G carriers who share a common 
haplotype on the disease allele defined by 4 exonic SNPs and two polymorphic 
microsatellites spanning the locus with phase determined by a cluster of carriers in 
UK Family 2, confirming a common founder (Supplementary Figure 1) (primers 
Supplementary Table 4). The minimal haplotype is defined by a physical stretch of 
2.5MB of genomic DNA spanning the ANXA11 locus, common to all p.D40G carriers. 
The core 4 SNP haplotype, located in exons of genes flanking ANXA11 is present in 
~5% of our extended FALS cohort (n=787, including C9orf72 expansion positive 
cases) and ~5% of Europeans from 1000genomes (n=514).  This suggests that the 
mutation arose on a European background. The maximal recombination region 
defining the limits of the p.D40G locus is 7.1MB and contains 23 genes 
(Supplementary Figure 2). Interrogation of exome sequencing data found that no 
p.D40G carriers shared any additional protein-changing variants in the 23 genes 
within this region. 70.3–97.2% of coding bases were covered to a read depth >=10 
for each sample, and 97.9% of bases were covered by >=10 reads in at least one 
sample (Supplementary Table 5). This evidence indicates that p.D40G is the sole 
causal variant within this locus. 
 
(iii) ANXA11 mutations in FALS and SALS cluster in the N-terminus 
Additional ANXA11 variants identified in the FALS cohort were two unrelated 
individuals carrying a c.112G>A, p.G38R variant (rs81930608) that was absent from 
local UK and Italian exome controls (n=4505). Although the p.G38R variant is 
present in 5/31804 NFE ExAC exomes it is still significantly associated with FALS in 
our cohort (p=0.004, 2-tailed Fishers exact test). Novel p.G175R (c.523G>A) and 
p.R346C (c.1036C>T) variants were also detected in two index cases. The p.G175R 
was also present in an affected sibling with ALS (Fig 1C) confirming segregation with 
disease. All FALS cases possessing ANXA11 variants were negative for exonic 
coding mutations in all known ALS genes including SOD1, TARDBP, FUS, PFN1, 
UBQLN2, MATR3, CHCHD10, TBK1, OPTN, VAPB, ANG, SQSTM1, CCNF, 
TUBA4A, C21orf2, NEK1 and VCP. 
All coding exons of ANXA11 were Sanger sequenced in an additional 180 British 
SALS cases (primers listed in Supplementary Table 4).  As previously mentioned, an 
additional D40G case was identified as well as an individual carrying a p.G189E 
(c.566G>A) variant, present once in local controls (n=4505) and 14 times in the 
ExAC NFE sub-population (n=33,140). Interestingly p.G189E is also present once in 
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ALSdB (http://chgv.org/alsdb/index.jsp). The last variant, located in the first annexin 
domain, was a p.R235Q (c.704G>A) change absent in local controls (n=4505) but 
present once as a low quality variant call in ExAC. Of note, ALS cases carrying 
ANXA11 mutations did not carry the R230C risk allele (rs1049550) that is associated 
with Sarcoidosis [19]. All variants found in FALS and SALS cases are listed in 
Supplementary Table 6 with control database frequencies and various computational 
predictions of pathogenicity.  
 
Four of the six mutations in Annexin A11 cluster with p.G38R and p.D40G within the 
long N-Terminus implying that this region has functional importance. All mutation 
positions are completely conserved in mammals and those in the annexin domains 
are also conserved in all currently sequenced birds, amphibians and reptiles (Fig 
1D).  
 
(iv) ANXA11 D40G cases have late disease onset and cytoplasmic immuno-
reactive inclusions in post mortem tissue 
 All patients with ANXA11 mutations had late disease onset (average 67 yrs) with a 
classical ALS phenotype without features of dementia (Supplementary Table 7). Five 
of six patients carrying the p.D40G variant had bulbar onset. Post mortem tissue was 
available from a SALS case carrying the p.D40G variant showing classical 
pathological features of ALS with a unique feature of large Annexin A11 
immunoreactive inclusions that were absent from other ALS cases or controls (Fig 2). 
Spinal cord sections revealed marked neuronal loss within the anterior horns. There 
was marked myelin pallor and astrogliosis in the anterior and lateral corticospinal 
tracts. Many surviving motor neurons contained cytoplasmic inclusions positive for 
p62 and phospho-TDP-43 (Fig 2A). Phospho-TDP-43 inclusions were also found in 
the medulla, temporal neocortex and hippocampus. Annexin A11 staining of spinal 
cord sections showed numerous neuronal cytoplasmic inclusions (NCIs) in the 
perikaryon and proximal axon (Figs 2B-E). These included skein-like (Fig 2B), large-
caliber tubular-shaped structures (Figs 2C-D) as well as filamentous and more 
complex basket-like inclusions (Fig 2E). Annexin A11 positive NCIs were also 
evident in small numbers in the motor cortex, dentate gyrus of the hippocampus and 
temporal neocortex sometimes accompanied by abundant torpedo-like neuritic 
structures in the neuropil (Fig 2F). Occasional, sparse Annexin A11 positive NCIs 
and neurites were also seen in the occipital lobe but no staining was observed in 
cerebellum. Staining for the amyloid precursor protein, Neurofilament (light, medium 
and heavy) and β3 tubulin was negative. SALS (n=13) devoid of known mutations 
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were negative for Annexin A11 NCIs in spinal cord (Figure 2G), as were 2 C9orf72 
expansion positive cases and a SOD1 positive case with a p.D101G mutation (Figs 
2H-J). Additionally, tissue from 3 ALS/FTD cases (Fig 2K), 3 Alzheimer’s (Fig 2L) 
and 3 Parkinson’s were negative for Annexin A11 positive NCIs in the cortex (n=2) 
and spinal cord (n=1) for ALS/FTD and in cortical and brainstem tissue for AD and 
Parkinson’s respectively. Spinal cord Annexin A11 staining was negative in 13 
controls (Figure 2M) (including frontal and temporal cortex and medulla regions in 3 
controls). Double fluorescent labelling of phospho-TDP-43 and annexin A11 in spinal 
cord neurons showed no evidence of co-localization (Fig 2N and O). Some Annexin 
A11 positive aggregates were ubiquitinated (Fig P). The cytoplasmic aggregation 
seen in post-mortem tissue from the D40G patient may be due to enhanced Annexin 
A11 expression due to an additional promoter mutation. However, screening of the 
ANXA11 promoter identified no novel, rare or common variants (MAF<0.05) in any of 
the cases carrying ANXA11 mutations. Furthermore, protein expression of lysates 
made from frontal cortex tissue of the SALS case possessing the p.D40G change did 
not show any changes in expression due to the mutant D40G allele compared to 3 
age and sex matched controls (Supplementary Figure 3).  
 
(v) Over-expressed Annexin-A11R235Q forms foci in mouse Primary Motor 
Neurons that are insoluble 
In order to understand the functional significance of these variants we undertook a 
series of cellular studies of mutations identified in our exome set.  We generated 
Annexin-A11WT, Annexin-A11G38R Annexin-A11D40G and Annexin-A11R235Q tagged with 
hemagglutinin (HA) or GFP at the C-terminus. Constructs were expressed in mouse 
primary motor neurons (PMNs) and human embryonic kidney 293 (HEK) cells. PMNs 
transfected with Annexin A11-HAWT constructs showed nuclear and cytoplasmic 
localization. In the cytoplasm Annexin A11 was present in larger vesicle-like 
structures, smaller foci structures and diffusely distributed throughout the soma, 
axons and dendrites (Fig 3A). Apart from Annexin A11-HAR235Q, which was elevated 
in the cytoplasm, there was no evidence that the other mutations affected the 
distribution between the nucleus and cytoplasm (Fig 3B) [32]. The Annexin A11-
HAR235Q mutant appeared to aggregate into foci, was never associated with vesicle-
like structures and diffuse staining was absent (p<0.001) (Fig 3C). Annexin A11-
HAD40G had a similar pattern to WT but Annexin A11-HAG38R displayed significantly 
less association with the vesicle-like structures (p=0.005). Annexin A11-GFPR235Q in 
HEK cells showed marked aggregation into ubiquitin and p62 positive inclusions that 
were also specific for endogenous Annexin A11 antibody and confirmed by western 
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blot (Supplementary Figure 4).  Annexin A11-GFPR235Q also produced high molecular 
weight species on western blot that were insoluble (Figs 3D-E) (p=0.007).  
 
(vi) Annexin-A11R235Q sequesters wild-type Annexin-A11 
We also investigated whether the aggregation-prone R235Q mutation recruits WT 
Annexin A11. We did this by co-transfecting SH-SY5Y cells with either Annexin A11-
GFPWT and Annexin A11-HAWT or Annexin A11-GFPR235Q and Annexin A11-HAWT 
constructs (Figure 4a). The merge of Annexin A11-HAWT and Annexin A11-GFPWT 
showed nuclear and diffuse cytoplasmic staining (top panel), whereas Annexin A11-
GFPR235Q cytoplasmic puncta and WT-HA showed co-localization (bottom panel). 
This suggests that insoluble, mutant Annexin A11 recruits wild-type Annexin A11. 
This was confirmed by firstly conducting a solubility assay on HEK cells co-
transfected with Annexin A11-HAWT and either Annexin A11-GFPWT or Annexin A11-
GFPR235Q, and secondly by immunoprecipitation (IP) and analyzed by Western blot. 
For the solubility assay, only the insoluble urea fraction of the Annexin A11-HAWT / 
Annexin A11-GFPR235Q co-transfection contained Annexin A11-HAWT compared to the 
WT-Annexin A11HA/GFP co-transfection (Figure 4b), demonstrating that the insoluble 
R235Q mutant can sequester wild-type Annexin A11. Furthermore, co-transfection of 
HEK cells with Annexin A11-HAWT and Annexin A11-GFPR235Q, and pulldown with 
rabbit-GFP antibody and blotting with mouse-HA, demonstrated co-precipitation of 
Annexin A11-HAWT with clear banding of higher molecular weight insoluble species 
Figure 4c). This provides evidence that mutant Annexin A11 species recruits WT 
Annexin A11 and thus may act in a dominant negative manner. 
 
(vii) Annexin A11 mutants abolish binding to Calcyclin  
Residues 50-62 in Annexin A11 bind calcyclin (encoded by S100A6) [33] and are in 
close proximity to the p.G38R and p.D40G mutations, therefore we sought evidence 
for any effect on their interaction. Calcyclin is a 10kDa protein that contains 2 EF-
hand calcium-binding motifs [34]. Jpred4 secondary structure predictions [35] on an 
alignment of all mammalian Annexin A11 orthologue sequences predicted that 
residues 40-44 and 51-59 form dual amphipathic helices  (Supplementary Figure 
5A). These helices mirror those seen in Annexin A1 which in the absence of calcium 
are embedded within the annexin core but are released on calcium activation, 
facilitating its binding to S100A11 and also mediating calcium-dependent protein-
membrane interactions [36, 37] (Supplementary Figure 5B-C). Whilst the N-terminus 
of Annexin 11 is much longer than, and highly divergent from the N-terminus of 
Annexin 1, the high conservation of the first 4 residues in the second helix (QEYV in 
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Annexin 1 versus QDYL in Annexin 11) imply a possible conserved binding site in the 
annexin core and is additional evidence for a similar mechanism of action. Both the 
Annexin A11 p.G38R and p.D40G variants are predicted to prevent or severely 
reduce formation of the first amphipathic helix (Supplementary Fig 5D). Extending 
this analysis to 22 rare and common polymorphisms listed in ExAC, spanning the 
D40 residue, predicted no abolition of the first or second N-terminal amphipathic 
helices (Supplementary Figure 6) suggesting that this disruption of structure is 
disease specific. 
 
In order to assess the effects of mutations in Annexin A11 on calcyclin binding we 
performed binding assays of Annexin A11-GFPWT and the Annexin 
A11G38R/D40G/G189E/R235Q mutants using a previously published in-vitro IP assay [38] 
(also methods). As anticipated, Annexin A11-GFPWT co-immunoprecipitated with 
calcyclin, confirming calcyclin–Annexin A11 binding. Annexin A11-GFPD40G severely 
disrupted calcyclin binding, as did Annexin A11-GFPG189E and Annexin A11-GFPR235Q 
mutants (Figure 5A). Annexin A11-GFPG38R binding however was markedly increased 
compared to WT. To assess the specificity of the loss of calcyclin binding due to 
ANXA11 mutants, we conducted binding assays with four ANXA11 polymorphisms 
present in ExAC. These were a rare p.D40H variant (once in ExAC, rs368751524) 
not detected in our ALS cases and 2 common NFE N-terminal polymorphisms 
flanking p.D40G ie. p.P8L (rs147334030, MAF 0.011) and p.R191Q (rs2229554, 
MAF 0.07) and the p.R230C SNP associated with Sarcoidosis (rs1049550, MAF 
0.44). These polymorphisms behaved in the same manner as wild-type and did not 
abolish calcyclin binding (Supplementary Figure 7) when compared to the p.D40G 
and p.R235Q mutations. Therefore, disruption to calcyclin binding in ALS cases 
harbouring ANXA11 mutations is disease specific. No differences were observed in 
Annexin A11 binding to other known binding partners ALG2 and Sorcin 
(Supplementary Figure 8).  
 
(viii) Calcyclin is over-expressed in astrocytes of the corticospinal tract in ALS 
patients 
Spinal cord sections from the ALS patient carrying the p.D40G mutation were stained 
with anti-calcyclin antibody. Although there was no observable difference in neuronal 
staining between the ALS case and controls, very high levels of calcyclin expression 
were detected in the cytoplasm of astrocytes in the lateral corticospinal tracts 
compared to controls (Figure 5Bi-ii). This is not a mutation-specific event as elevated 
calcyclin expression was also seen in apparent sporadic ALS cases without known 
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ALS gene mutations (Figure 5Biii). Increased expression of calcyclin in astrocytes of 
the corticospinal tract has previously been reported in sporadic ALS cases as well as 
SOD1G93A transgenic mice, but the functional significance of this observation is 
unknown [39, 40].  
  
(ix) Calcyclin co-overexpression in HEK cells clears R235Q aggregates  
We also explored the impact of calcyclin interaction on Annexin A11 solubility. FLAG-
CalcyclinWT was co-transfected with Annexin A11-GFPWT or Annexin A11-GFPR235Q in 
HEK cells and assessed by NP40 insolubility assay and western blot. Remarkably, 
the increase in calcyclin expression reduced levels of soluble WT and p.R235Q but it 
completely cleared insoluble Annexin A11-GFPR235Q (Figure 5C). This suggests that 
increasing calcyclin may inhibit Annexin A11 expression or enhance Annexin A11 
clearance via a degradation pathway. Treating the cells with the ubiquitin 
proteasome inhibitor MG132 treatment for 24hrs significantly restored Annexin A11-
GFPR235Q insolubility (Figure 5D, p<0.001). 
 
Discussion  
Using a stringent filtering strategy on a large cohort of FALS exomes (n=694) in 
conjunction with a shared variant analysis of 50 Caucasian kindreds we identified a 
non-synonymous mutation p.D40G in ANXA11, shared in two UK families but absent 
from >70,000 control exomes. The mutation segregated with disease in the two UK 
families and an additional Italian FALS proband also carried the p.D40G variant. 
Sequencing of 180 unrelated UK SALS identified a fourth p.D40G individual, 
providing further evidence that p.D40G is causative for ALS. An independent 
simulation strategy designed to ascertain the significance of mutations identified 
multiple times in our ALS cohort (n=874) found the D40G mutation (n=4) to be 
associated with ALS, p=0.0102. All p.D40G individuals had a common founder 
p.D40G haplotype, which adds to the growing list of published founder mutations that 
are abundant in ALS [41-43]. In addition a novel p.G175R mutation segregated with 
disease in one kindred and several other ANXA11 mutations clustered in the N-
terminus of the molecule were also associated with ALS.  
 
Our study was limited by several factors. The primary shared variant analysis that 
formed the basis of the study relied on the pathogenic variant for each family being 
novel, nonsense, mis-sense or splicing, and located in a region sequenced to an 
adequate depth in all family members. The lack of power when conducting linkage in 
the D40G kindreds necessitated us devising a new simulation-based approach to the 
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determination of significance, applied to the case of novel variants found multiple 
times in a disease cohort.	 Furthermore the high underlying heterogeneity of ALS, 
highlighted by discovering one novel gene from 50 families, is an on-going challenge 
in the identification of new causative genes.  
 
Mutations in ANXA11 present a distinct clinical phenotype characterized by late-
onset classical ALS with 5 of 6 p.D40G cases having bulbar onset disease. Post 
mortem tissue from a p.D40G ALS case displayed abundant Annexin A11-positive 
aggregates within motor neurons in spinal cord and neurons and neuropil in the 
neocortex and hippocampus in addition to the classical features of neuronal loss, 
phospho-TDP-43 inclusions and astrogliosis.  
 
Annexin A11 is a phospholipid binding protein, which may participate in vesicle 
trafficking as it has been reported to play a role in apoptosis, exocytosis and 
cytokinesis and forms phospholipid vesicles in-vitro in a calcium dependent manner 
[18, 44]. Annexin A11 co-localises with calcyclin in the nuclear envelope during 
prophase of mitosis [45], however little is known about its role in post-mitotic neurons 
and it’s trafficking within the cell. From our study Annexin A11 does form vesicle-like 
structures in PMNs (Figure 3), which suggests a role for Annexin A11 in vesicular 
transport. Recent evidence has found that Annexin A11 plays an important structural 
role in regulating the delivery of vesicular cargoes from the endoplasmic reticulum to 
the Golgi apparatus which is mediated through its binding to ALG2 to stabilize 
Sec31A [46]. In our study, Annexin A11 mutations did not directly affect ALG2 
binding and it is therefore more likely that the mutant alleles disrupt vesicular 
trafficking by altered binding to calcyclin.  
 
Annexin A11 mutations may behave in a dominant negative manner and interfere 
with the normal function of Annexin A11 in neurons, which is currently unknown. The 
sequestering of wild-type Annexin A11 by the R235Q mutation, located in the first 
annexin domain, offers this plausible mechanism (Figure 4). However most ANXA11 
mutations are N-terminal and do not aggregate or form insoluble aggregates in our 
in-vitro functional studies. In spite of this, the N-terminal p.D40G mutation under 
endogenous, long-lived conditions can aggregate as evidenced by abundant 
immuno-reactive inclusions seen in post mortem tissue from the p.D40G SALS case 
(Figure 2). Although the R235Q mutant failed to bind to calcyclin, over-expression of 
calcyclin completely cleared insoluble p.R235Q aggregates by facilitating 
proteasomal degradation (Figure 5). Calcyclin is known to play a role in proteostasis 
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when it forms a functional complex with calcyclin binding protein (CACYBP), and the 
RING type E3 Ubiquitin Ligase SIAH-1 that regulates ubiquitination and degradation 
of beta-catenin [47]. More subtle differences in calcyclin binding were also observed 
for other Annexin A11 mutants. Calcyclin binding was inhibited by p.D40G and 
p.G189E mutations and consistently increased above wild-type for the p.G38R 
mutant. Therefore loss of calcyclin binding may result in an accumulation of 
cytoplasmic Annexin A11 promoting its aggregation. As most N-terminal mutations 
abolish Calcyclin binding, this suggests Calcyclin may also be necessary for Annexin 
A11 structure and/or function and N-terminal mutations may therefore act by a loss of 
function mechanism. As the p.R235Q mutation sequesters WT Annexin A11, it would 
also lead to aborted calcyclin binding in the same manner as the p.D40G mutation, 
therefore a possible common outcome would be a loss of function.  
 
We and others have shown that the levels of calcyclin are greatly increased in 
astrocytes in apparent sporadic ALS cases as well as the one carrying the p.D40G 
mutation [39, 40]. Even though this phenomenon is not solely linked to ANXA11 
mutations, it raises the possibility that increased astrocytic calcyclin expression is a 
response to defective proteostasis. Interestingly, cells in which TDP43 is knocked-
down demonstrate a significant increase in the expression of calcyclin transcripts [48, 
49]. Additionally, elevated calcyclin concentrations can form oligomers that have 
amyloidogenic properties that have been shown to seed SOD1 aggregation [50].  
 
In summary, we have identified 6 novel, or extremely rare, ANXA11 variants in 13 
individuals, which account for ~1% of familial and 1.7% of apparent sporadic ALS 
cases in our cohort. Functional investigation of four of these variants (p.G38R, 
p.D40G, p.G189E and p.R235Q) has yielded initial insights into a causative role in 
ALS biology. However, the contribution of the remaining ANXA11 variants to disease, 
if any, is yet to be determined. ANXA11 variants alter binding to calcyclin, which can 
lead to cytoplasmic aggregation in transfected cells and neuronal cytoplasmic 
inclusions in a patient carrying the D40G mutation at post mortem. The identification 
of ANXA11 variants presents a new field of ALS investigation and highlights the 
significance of calcium binding proteins and intracellular trafficking in ALS 
pathobiology [51]. Further work investigating how mutations affect the folding of 
Annexin A11, it’s binding to calcyclin and the effect on vesicular transport and TDP-
43 aggregation will clarify the underlying disease mechanisms. 
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Materials and Methods 
 
DNA Samples 
Full patient consent was provided by FALS and SALS index patients and control 
individuals for research purposes. All patients had a diagnosis of definite or probable 
ALS based on revised El Escorial criteria [52] with at least one relative known to 
have ALS+/-FTD. All FALS were pre-screened for the C9orf72 intronic 
hexanucleotide expansion, and any positive samples excluded from this analysis.  
The discovery cohort was comprised of 694 FALS probands sourced from the United 
States (266), UK (193), Italy (138), Spain (33), Germany (25), Ireland (17), Canada 
(9), the Netherlands (9), Belgium (3) and New Zealand (1). An additional 60 affected 
relatives of these probands, representing 50 families, were also exome sequenced in 
tandem for segregation analysis. Sequence data for 102 of the cases in the cohort 
were obtained, with permission, from the dbGAP repository (NIH Exome Sequencing 
of Familial Amyotrophic Lateral Sclerosis, NINDS, phs000101.v4.p1, Traynor).  
 
Exome Sequencing and Bio-informatic Analysis  
Paired-end FASTQ files from Illumina exome sequencing were aligned to the hg19 
human reference using NovoCraft Novoalign and variants called with samtools v1.1 
mpileup. VCF files were filtered at DP>=10, GQ>=20, MQ>=50, and indels 
normalized with bcftools v1.1 norm. Functional annotation, pathogenicity predictions 
and matches to 1000 genomes were added with table_annovar.pl [53], whilst all 
other annotation was added via custom perl scripts. Variants were filtered out if they 
were not novel (defined as being present in either 1000 genomes 
(http://www.1000genomes.org), ExAC (http://exac.broadinstitute.org/), ESP 
(http://evs.gs.washington.edu/EVS/), UK10K (http://www.uk10k.org/) or 672 In-house 
exome controls), or if they were located at positions with a read depth <10 in >25% 
of ExAC samples. Insertions and deletions were excluded due to the increased error 
rate in matching variants to control databases assembled and called by alternative 
pipelines. Synonymous and intronic variants were assessed by Netgene2 and 
Genesplicer, and excluded if no changes in scores compared to the reference allele 
were observed at locations matching to known Refseq acceptor or donor splice sites. 
Common ancestry between samples was taken from existing familial annotation 
where available, and also deduced from IBD analysis in Plink v1.07 [54]. Two parallel 
approaches were then taken to narrow down this set of high quality, novel, protein-
changing variants to those most likely to be pathogenic in ALS. Firstly, we identified 
the variants that were shared between all exome-sequenced cases of the 50 families 
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for which data was available for more than one family member, an approach used 
successfully in many Mendelian disorders [55]. Secondly, we identified all the 
variants that were shared by three or more probands, selected as the sample from 
each of the 694 families with the highest proportion of the exome covered at a depth 
>=10x. The read alignments were manually inspected for all resulting variants and 
clearly-identifiable false positives removed, resulting in an effective revised filter cut-
off of GQ>=90. 
 
Simulation studies using ExAC variant calls 
In order to assess the null hypothesis, that finding a novel protein-changing variant 
>=4 times would also be likely to occur in a non-disease cohort, a simulation strategy 
was chosen based on variant calls from the ExAC database. The VCF files for the 
r.0.3 release of ExAC were annotated and filtered by the identical pipelines described 
above, with the exception that only variants present within the NFE (Non-Finnish 
European) population of ExAC samples were considered. ExAC NFE heterozygote 
and homozygote counts were added together to give NFE carrier counts. The data 
was then further filtered to only retain variants shared by >=4 carriers (n=67,154). 
These variants were then randomly distributed across 33,370 simulated ExAC 
European individuals. The FALS + SALS cohort was then simulated by randomly 
selecting 874 of these individuals (694 FALS probands + 180 SALS) from the total 
pool. To replicate the variant being novel across the remainder of the dataset, each 
variant in the filtered ExAC dataset was rejected if all NFE carriers were not within 
the simulated cohort. A cohort was deemed to have passed if at least one variant 
met the above criteria. The p-value was calculated as the proportion of cohorts that 
passed, after sufficient permutations of random cohorts had been generated to 
achieve a stable result to 2 significant figures. All random integers were generated 
using the perl CPAN Math::Random::Secure irand function. 
 
Genetics Screening 
All coding exons of ANXA11 (Refseq ID NM_145869) were amplified using standard 
polymerase chain reaction procedures. At least 100bp of flanking intronic sequence 
was included to detect splice site mutations (Primers listed in Supplementary Table 
4). Amplicons were directly sequenced with Big-Dye Terminator v1.1 on an ABI3130 
genetic analyzer (Applied Biosystems Pty Ltd, Warrington, UK) and sequence 
chromatograms analyzed for mutations using Sequencher 4.10 directly by eye (Gene 
Codes Corporation, Ann Arbor, Michigan, USA). Reconfirmation of novel mutations 
was conducted by re-dilution of stock DNA and re-PCR and direct sequencing. Rare 
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variant positions in ANXA11 were also filtered against 3596 Italian exome controls. 
Nine hundred and nine local control UK samples matched for sex and age were 
assayed for ANXA11 genomic SNP positions for the G38R, D40G, G189E and 
R235Q mutations using KASPar genotyping methods by LGC Genomics (LGC 
Genomics, Teddington, UK).  
 
Haplotype Study 
Microsatellites surrounding the ANXA11 locus were identified using Hg19 build of the 
UCSC Genome Browser (http://www.genome.ucsc.edu/) and amplified by standard 
PCR with the forward primer incorporating a fluorescent FAM label. 1ul of PCR 
product was run using Fragment Analysis on an ABI3130 genetic analyzer. Allele 
sizing was conducted using GeneMapper V4. SNP markers rs41291392, 
rs17617713, rs72821609 and rs72805713 were genotyped using standard PCR and 
direct sequencing (primers listed in Supplementary Table 4). The genomic haplotype 
locus figure (Supplementary Figure 2) was drawn using the ‘Dalliance’ program [56]. 
 
Plasmids and Cloning 
A cDNA encoding ANXA11 was amplified from pEGFP-C3/ANXA11 [57] with the 
following pair of oligonucleotides with a BamHI site (underlined): 5’-
TAGGATCCACCATGAGCTACCCTGGCTATCC-3’ (sense) and 5’-
GCGGATCCGAGTCATTGCCACCACAGATCTT-3’ (antisense). The DNA fragment 
obtained was subcloned into the pCR-BluntII-TOPO (Invitrogen). To construct 
pANXA11-GFP, a BamHI fragment from pCR-Blunt II-TOPO/ANXA11 was inserted 
into the BamHI site of pGFP-N-SGG [58]. Single amino acid changes (G38R, D40G 
and R235Q) were introduced into pANXA11-GFP by PCR-based site-directed 
mutagenesis. To construct pFLAG-S100A6, an EcoRI fragment of pCR2.1 
TOPO/S100A6 (kindly provided by Dr. Kiyotaka Hitomi, Nagoya University, Japan) 
was inserted into the EcoRI site of pCMV3xFLAG-B [59]. A cDNA encoding sorcin 
was amplified from human fetus cDNA library (Clontech) and subcloned into the 
pCMV-Tag 2A (Stratagene) to construct pFLAG-sorcin. An expression vector 
encoding ALG-2 N-terminally tagged with FLAG (pFLAG-ALG-2 RNAiR) was 
described previously [60]. 
ANXA11 expression vectors (Gateway pcDNA3.1/nV5-DEST, Invitrogen) encoding c-
terminal HA tagged ANXA1 wild type (WT), G38R, D40G and R235Q mutants were 
used in this study. Site-directed mutagenesis was performed according to the 
manufacturer’s protocol (Quickchange II Site-Directed Mutagenesis Kit, Stratagene) 
using a ANXA11-HA tagged pDONR221 entry clone plasmid to produce constructs 
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harboring the novel mutants identified in this study. The pDONR221-ANXA11 mutant 
constructs were then recombined with pcDNA3.1/nV5-DEST to create the final 
mutant expression constructs. All constructs were verified by sequencing.  
 
Antibodies 
Mouse monoclonal anti-GFP at 1/2000 (cat.no sc-9996, Santa Cruz, Dallas, USA), 
mouse monoclonal anti-GAPDH (cat.no G8795, Gillingham, UK) and mouse 
monoclonal Histone H3 (cat.no 96C10, New England Biolabs Hitchin, UK) were used 
for detecting lysate, soluble and insoluble fractions on Western blot from NP40 
insolubility assays. In the Annexin A11:EF-hand proteins (calcyclin, ALG-2 and 
sorcin) binding assays, mouse monoclonal anti-FLAG (cat.no. F3165, Sigma-Aldrich) 
was used to immunoprecipitate FLAG-tagged EF-hand proteins, and mouse 
monoclonal anti-GFP (cat.no. sc-9996, Santa Cruz) and mouse monoclonal anti-
FLAG or rabbit polyclonal anti-FLAG (cat.no. F7425, Sigma-Aldrich) were used to 
detect GFP-fused proteins and FLAG-tagged proteins, respectively. Polyclonal 
Rabbit Anti-ANXA11 (cat.no. 10479-2-AP, Proteintech, Manchester, UK) was used 
for ANXA11R235Q staining of HEK cells (Supplementary Figure 4) and spinal cord of 
the D40G SALS patient, SALS patient devoid of known ALS causing mutation, other 
neurodegenerative disorders and controls. Polyclonal rabbit Anti-calcyclin (cat.no. 
10245-1-AP, Proteintech) was utilized for IHC of patient and control post mortem 
tissue and detection of FLAG-tagged calcyclin by Western blot in HEK cells.  
 
Transfection of HEK and SH-SY5Y cells  
HEK293T and SH-SY5Y cells were maintained in DMEM with high glucose plus 
Glutamax and DMEM/F12 respectively (Life Technologies, Paisley, UK) with 10% 
fetal bovine serum, 100U/mL penicillin, and 100 mg/mL streptomycin in a water 
jacketed incubator at 5% CO2. For solubility fractionation, transfections were 
performed in 12-well plates with 500 ng of plasmid DNA and 1.5ml Fugene HD 
(Promega, Southampton, UK) per well, as per the manufacturer’s protocol. For 
immunofluorescence, HEK293T cells were plated at 25,000 cells/cm2 on 13 mm 
diameter, 1.5-mm-thickness coverslips coated with poly-D-lysine (Sigma-Aldrich, 
Dorset, UK) in 24-well plates and transfected with 250ng of DNA and 0.75ml of 
Fugene HD. SH-SY5Y cells were transfected in the same manner except the 
transfection reagent used was Lipofectamine (Fisher Scientific, Loughborough, UK). 
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FLAG-S100A6 and ANXA11-GFP Binding Assays  
HEK293 YS14 cells (a sub-cloned HEK293 cell line) [61] which had been plated on 
the previous day, at a density of 1.8 x 106 cells per 10 cm dish were transfected with 
expression plasmids using Polyethyleneimine (150 µg) (Polysciences) and then 
cultured for 24 hr. To attain equivalent expression level, the following amounts of 
plasmid DNA for SGFP2-fused proteins were used: pSGFP2-N-SGG, 3 µg; 
pANXA11WT-SGFP2, 5 µg; G38R, 6 µg; D40G, 7 µg; G189E, 6 µg; R235Q, 10 µg; 
P8L, 5 µg; D40H, 5 µg; R191Q, 5 µg; R230C 5 µg. The cells were washed and 
harvested with PBS, suspended in 210 µL per 10 cm dish (for cells expressing 
SGFP2-fused proteins in the case of interaction with calcyclin), 470 µL per 10 cm 
dish (for cells expressing SGFP2-fused proteins in the case of interactions with ALG-
2 or sorcin) or in 350 µL per 10 cm dish (for cells expressing FLAG-tagged proteins) 
of lysis buffer (20 mM HEPES-KOH, pH 7.2, 142.5 mM KCl, 2.5 mM MgCl2) 
containing 0.2% Triton X-100, 10 µM EGTA, protease inhibitors (1 µM E64, 3 µg/mL 
leupeptin, 0.1 mM pefabloc, 2 µM pepstatin A, 0.2 mM PMSF) and phosphatase 
inhibitors (50 mM NaF, 10 mM β-glycerophosphate, 1 mM Na3VO4). After 30 min on 
ice, the cell lysates were centrifuged at 15,000 g for 10 min at 4°C. The cleared 
lysates of the cell expressing GFP-fused proteins were divided into aliquots of 200 µL 
and mixed with 100 µL of the cleared lysates of the cells expressing FLAG-tagged 
proteins. Twenty µL of the mixture was taken as input. The samples were rotated at 
4°C for 90 min in the presence of 100 µM of CaCl2, mixed with 0.8 µg of mouse 
antibody against FLAG (M2) (cat.no F7425, Sigma, Poole, UK) and rotated at 4°C for 
further 60 min. Then the samples were incubated overnight at 4°C with 10 µL of 
Dynabeads Protein G (Novex, Invitrogen). The beads were collected using a magnet 
and washed twice with 500 µL of lysis buffer containing 0.1% Triton X-100 and 100 
µM CaCl2. Washed beads were boiled for 5 min in 56 µL of 1x SDS-PAGE sample 
buffer. Four µL of input and 8 µL of IP (for detection of FLAG-tagged proteins) or 1.2 
µL of input and 12 µL of IP (for detection of GFP-fused proteins) were run on a 
western blot. 
 
FLAG-Calcyclin and ANXA11-GFP over-expression in HEK cells 
500ng of ANXA11-GFPWT and ANXA11-GFPR235Q constructs were co-transfected with 
500ng of FLAG-Calcyclin in a 6 well dish of HEK cells plated at 25,000 cells/cm2. 
Untreated ANXA11-GFPWT and ANXA11-GFPR235Q were co-transfected with empty 
pEGFP-C1 vector (Clonetech Pty Ltd, Mountain View, California, USA). Duplicate 
wells of ANXA11-GFPWT and ANXA11-GFPR235Q transfected cells were also treated 
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with 0.5µM MG132 24hrs before harvesting (48 hours post transfection). Cells were 
harvested and processed as per the NP40 insolubility assay below. 
 
Primary Motor Neuron (PMN) Cultures  
Motor neurons were isolated from mouse embryos, cultured and transfected as 
described [62]. Cells were fixed 1 or 4 days after transfection and processed for 
immunofluorescence. After antigen retrieval in citrate buffer for 20 minutes and 
blocking in 5% bovine serum albumin for 1 hour, cells were hybridized overnight at 
4°C with HA primary antibody (Covance, 1:1000) Alexa488 or Alexa594-conjugated 
secondary antibodies (Jackson Immuno-research) were incubated for 1 hour at room 
temperature. Vesicles were defined as structures with a diameter between 0.5µm to 
1.9 µm (mean 1 µm) and foci 0.16µm to 0.5 µm (mean 0.3 µm).   
 
Protein Fractionation, Insolubility Assay and Western Blot 
ANXA11-GFP WT and mutant construct transfected HEK cells were harvested at 48 
wells post-transfection and fractionated using a NP40 solubility assay as described 
previously [63]. Lysate and soluble fractions were quantified using a BSA standard 
protein assay and 5ug of lysate and soluble fractions analysed by Western blotting. 
The same volume of insoluble fraction was loaded as per cell lysate. Nitrocellulose 
membranes were probed with mouse monoclonal anti-GFP at 1/2000 dilution, mouse 
monoclonal ant-GAPDH 1/2000 dilution and mouse monoclonal Histone H3 1/1000 
dilution in 1% Skim Milk and PBS-Tween. Band intensities were quantified using 
Image J (http://imagej.nih.gov/ij/). Membrane imaging was conducted with 
fluorescent secondary antibodies, Goat Anti-rabbit and Anti-mouse IgG (H+L) Dylight 
680 Conjugate (Thermolifesciences cat #35568 and #35521) on a Licor Odyssey 
Imager. 15µg of frontal cortex lysate was run on PVDF membranes and probed with 
1/400 Proteintech Rabbit ANXA11 and developed using ECL and visualized using 
anti-rabbit chemi-luminescent horse raddish peroxidase (HRP) (Millipore Immobilon 
cat# WBKLS0500). 
 
Co-transfection Immuno-precipitation 
Individual wells of a 6 well plate were seeded with HEK cells and transfected at 70% 
confluence with either Annexin A11-GFPR235Q or Annexin A11-GFPR235Q plasmid. A 
duplicate set of wells with Annexin A11-GFPWT or Annexin A11-GFPR235Q were co-
transfected with Annexin A11-HAWT.  At 48hrs cells were harvested in 
immunopurification buffer (50mM Tris pH7.4, 150mM NaCl, 1% TritonTM X-100, 
100uM CaCl2 with protease and phosphatase inhibitor). The cell lysate was collected 
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and incubated with immunopurification antibody (rabbit anti-GFP, cat.no AB290 
Abcam) and Dynabead protein G (Life Technologies) overnight at 4oC. The 
Dynabead protein Antibody- protein complex was purified using magnetic separation 
and washed with immunopurification buffer before elution in loading buffer (variation 
on protocol described in [64]. Lysates, IP and flow through fractions were run on a 
nitrocellulose membrane and membrane imaging was conducted with fluorescent 
secondary antibodies and a Licor Odyssey.  
 
Statistical Analysis 
Statistical analysis of PMN immunofluorescence data, NP40 insolubility data and 
FACs Survival Data was performed with Graphpad Prism software.  Normality of the 
datasets was assessed with the D’Agostino-Pearson test. One-way ANOVA with 
Dunnett’s post hoc test or Kruskal-Wallis with Dunn’s post hoc test were performed 
depending on normality.  
 
Mutation modelling and Jpred Analysis  
The Refseq protein database was searched with human ANXA11 (NP_001148.1) via 
BlastP at the NCBI (http://blast.ncbi.nlm.nih.gov/Blast.cgi).  The highest matching 
sequence per vertebrate species from the first 250 results was aligned with all others 
using Muscle (http://www.ebi.ac.uk/Tools/msa/muscle/).  Sequences were removed if 
they had a better reciprocal match to a different human annexin gene or if they 
contained significant numbers of gaps, mismatching regions or consecutive “X”s, 
implying incomplete or mistranslated sequence. Fish were also excluded, as they 
consistently showed significant divergence along the majority of the N-terminus, and 
with the exception of the first 20 amino acids a satisfactory alignment to other 
taxonomic Classes could not be obtained. The resulting multiple alignment was hand 
edited in GeneDoc and submitted to JPred4 
(http://www.compbio.dundee.ac.uk/jpred4/) for secondary structure prediction. 
Predictions were also made for the ALS-associated variants G38R and D40G, and 
22 non-ALS variants from the ExAC database flanking these residues, by replacing 
every amino acid in the multiple alignment with the variant residue. Possible 
amphipathicity of any resulting alpha helices was tested by submitting the sequences 
to Helixator (http://www.tcdb.org/progs/helical_wheel.php). The procedure was then 
repeated for human ANXA1, but with this gene it was not necessary to exclude fish 
species from the alignment. 
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Neuropathology 
Brain tissue samples in 10% formalin-fixed, paraffin-embedded tissue blocks were 
available from the London Neurodegenerative Diseases Brain Bank (King’s College 
London, UK). Consent for autopsy, neuropathological assessment and research 
were obtained from all subjects and all studies were carried out under the ethical 
approval of the tissue bank. Block taking for histological and immunohistochemical 
studies and neuropathological assessment for neurodegenerative diseases was 
performed in accordance with standard criteria. 
 
Immunohistochemistry: 
Immunohistochemistry was carried out as per previously published protocols [65]. In 
brief, sections of 7µm thickness were cut from the paraffin-embedded tissue blocks, 
deparaffinised in xylene, endogenous peroxidase was blocked by 2.5% H2O2 in 
methanol and immunohistochemistry performed. To enhance antigen retrieval, 
sections were kept in citrate buffer for 10 minutes following microwave treatment. 
After blocking in normal serum primary antibody was applied overnight at 4°C.  
Following washes, sections were incubated with biotinylated secondary antibody 
(DAKO), followed by avidin:biotinylated enzyme complex (Vectastain Elite ABC kit, 
Vector Laboratories, Peterborough, UK). Finally sections were incubated for 10–
15 min with 0.5 mg/mL 3,3′-diaminobenzidine chromogen (Sigma-Aldrich Company 
Ltd, Dorset UK) in Tris-buffered saline (pH 7.6) containing 0.05% H2O2. Sections 
were counterstained with Harris’ haematoxylin and immunostaining analysed using a 
Leica microscope (Leica, Wetzlar, Germany).  
 
Double Immunofluorescence: 
7µm sections were cut from formalin fixed paraffin embedded blocks, dewaxed in 
xylene and dehydrated in 99% industrial methylated spirit. Sections were then 
pretreated by microwaving in citrate buffer and blocked using normal goat serum 
(1:10 for 45min). Primary antibodies were then applied and sections incubated at 4°C 
overnight. Sections were washed and secondary Alexa Fluor antibody (Invitrogen, 
Paisley, UK) applied for 45 min (in dark). Autofluorescence was quenched by 
incubating the sections in Sudan black for 10min followed by numerous washes in 
phosphate buffered saline before coverslip mounting using hard set media with 
DAPI. Sections were visualised using a fluorescent microscope (Zeiss Axiovert S 
100, Gottingen, Germany) and images captured using ImagePro Express (V6). 
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Figure Legends 
 
Main Figures 
 
Figure 1. Annexin A11 mutations identified in ALS patients following stringent 
filtering of exome sequencing data. (A and B) Pedigrees of UK Family 1 and 2 
respectively, carrying the p.D40G mutation. Family members for whom DNA was 
available for segregation analysis are labelled with M/W for a heterozygous mutant 
(A>G allele) or W/W for a homozygous reference allele. The gender has been 
anonymised for each individual.  Affected individuals with ALS are denoted by a solid 
black diamond, unaffected by white diamonds and unaffected carriers with a black 
dot. Affected family members exome sequenced as part of this study are marked 
with a blue star. (C) The G175R mutation segregates in both an index case and 
affected sibling. The ages of death, where data is available, is listed above each 
D40G carrier (affected and unaffected) (A), (B) or (C). (D) Schematic representation 
of the Annexin A11 molecule highlighting a clustering of mutations in the N-terminus 
(first 196 residues). Mutation positions in the N-terminus are fully conserved in 
mammals, and conserved in birds, amphibians and reptiles if in an annexin domain. 
Mutations in FALS are indicated by red boxes, and in SALS by blue boxes. The 
D40G mutation found in 2 index FALS and an affected sibling from each UK family, 
an Italian index case and a UK SALS (n=6) clusters with G38R in the N-terminus of 
the ANXA11 molecule. The binding site of calcyclin (labelled CACY) is located in the 
N-terminus, residues 50-62. 
 
Figure 2. TDP-43 and Annexin A11 immunohistochemistry from post-mortem 
spinal cord tissue of a SALS case harbouring the novel D40G mutation. (A) 
phospho-TDP43 positive cytoplasmic inclusion from anterior horn of the spinal cord.  
(B-E) Annexin A11 positive inclusions in motor neurons of the cord included skein-
like (B), filamentous and tubular- shaped structures (C-D). Occasional more “basket-
like” inclusions were seen in the cord (E). Abundant annexin A11 positive torpedo-
like neuritic structures were also present in the neuropil here seen in the motor cortex 
(arrows) (F). Representative spinal cord staining in a SALS case (n=15) negative for 
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ANXA11 mutations (G) and two C9ORF72 expansion positive cases (spinal cord and 
frontal cortex, H and I). ANXA11 staining was also negative in a SOD1 positive case 
harboring a p.D101G mutation (spinal cord, J). Similarly spinal cord cases of FTLD-
TDP43 (K, n=3) and Alzheimer’s cases (L, n=3) and control individuals (M, n=13) 
were also negative for annexin A11 inclusions.  Double labelling for phospho-TDP43 
(green) and Annexin A11 aggregates (red) (N-O). Co-staining for ubiquitinated 
aggregates (red= Annexin A11 and green=ubiquitin) showed occasional co-
localisation (P) (indicated by arrows). Scale bars - A, E, G and H- 30µm; B, C- 20µm; 
D-15µm; F, I, J, K, L- 50µm, M, N- 25µm, O, P- 50µm. 
 
Figure 3. Functional Annexin A11 studies in mouse Primary Motor Neurons 
and HEK cells at 4 days post transfection. (A) ANXA11-HAWT/G38R/D40G/R235Q 
transfected into PMNs display cytoplasmic vesicle-like structures for WT, G38R and 
D40G and a significant localization of smaller cytoplasmic foci in the cytoplasm for 
R235Q, (B) p=0.0004 (One way ANOVA and Dunnett's post hoc test, Bars represent 
mean and SEM). Vesicles were defined as structures with a diameter between 0.5µm 
to 1.9 µm (mean 1 µm) and foci 0.16µm to 0.5 µm (mean 0.3 µm).  (C) There was a 
significant proportion of foci associated with R235Q (p<0.0001, One way ANOVA 
and Dunnett's post hoc test) but a smaller proportion of vesicle like structures 
associated with G38R and a complete absence with R235Q (p=0.0051 and p<0.0001 
respectively, One way ANOVA and Dunnett's post hoc test). (D) R235Q ANXA11-
GFP forms high molecular weight detergent resistant aggregates in HEK cells. The 
lysate (L), soluble (S) and insoluble (I) fractions of HEK cells transfected with 
ANXA11-GFPWT/G38R/D40G/G189E/R235Q show R235Q to form high detergent resistant 
insoluble aggregates. (E) The level of R235Q insoluble fraction is statistically 
significant when compared with WT (p=0.007, One-way ANOVA with Dunnett’s post 
hoc test).  
 
Figure 4. The R235Q mutation sequesters WT Annexin A11. (A) Co-expression of 
ANXA11-HAWT and ANXA11-GFPR235Q in SH-SHSY cells demonstrated co-
localisation suggesting sequestering of ANXA11-HAWT by mutant ANXA11R235Q. 
Scalebars 10µm. (B) Expression of ANXA11-GFPWT and ANXA11-GFPR235Q 
replicated that seen in Figure 3D, with insoluble aggregates in the urea fraction seen 
only in ANXA11-GFPR235Q (Lanes 1-6). When co-expression of ANXA11-GFPWT or 
ANXA11-GFPR235Q with an equal amount of ANXA11-HAWT was conducted in HEK 
cells, there was an accumulation of ANXA11-HAWT in the insoluble urea fraction only 
when co-expressed with ANXA11-GFPR235Q - indicated by a red star (n=3) (Lanes 7-
30	
12). (C) Furthermore co-transfection of HEK cells with ANXA11-GFPR235Q and 
ANXA11-HAWT and immuno-precipitation (IP) with rabbit anti-GFP and probing with 
mouse-HA showed a direct sequestering of ANXA11-HAWT in the IP fraction (Lane 
6), including higher insoluble molecular weight species compared to vector and 
vector plus GFP (Top panel). Verification of the IP was shown by staining with 
mouse-GFP in Lanes 3 and 6 (Input and IP - Middle Panel) and positive staining of 
input ANXA11-HAWT in the Input and bead flow-through (FT) in the top panel. 
 
Figure 5. Calcyclin analysis: in-vitro binding assays with mutant Annexin A11 
constructs and staining of post-mortem tissue. (A) Western blot demonstrating 
lack of binding of FLAG-calcyclin to ANXA11-GFPD40G, ANXA11-GFPG189E and 
ANXA11-GFPR235Q compared to ANXA11-GFPWT by immunoprecipitation (IP) (n=3). 
The top panel shows GFP intensities of input and precipitated fractions, with IgG 
heavy (50kDA*) and light (25kDa**) chains indicated. The bottom panel illustrates 
input and IP levels of FLAG-calcyclin. (B) Cross-section of spinal cord showing 
calcyclin expression in (i) controls and (ii) a SALS case with the p.D40G mutation. 
High calcyclin expression can be seen in the lateral corticospinal tracts (arrows). (iii) 
SALS case devoid of known ALS causing mutation but also displaying strong 
expression of calcyclin in the lateral corticospinal tracts (arrows). Scale bars (i) 
40µm, (ii) 30µm and (iii) 25µm. (C) NP40 insolubility assay of co-expression of 500ng 
of ANXA11-GFPWT and ANXA11-GFPR235Q and 500ng of FLAG-calcyclin in HEK 
cells, demonstrating clearance of insoluble R235Q aggregates by calcyclin co-
expression. An equivalent amount of empty GFP Vector (500ng) was added to 
untreated WT and R235Q HEK cells. (D) Quantification of ANXA11-GFPWT/R235Q co-
expression experiment. Bands were quantified with ImageJ (http://imagej.nih.gov/ij/) 
and intensity levels calculated with respect to untreated ANXA11-GFPWT.  A one-way 
ANOVA test demonstrated significance of the untreated R235Q and R235Q 
treatment with calcyclin followed by 24hours MG132 treatment  (p<0.05 and p<0.001 
respectively, One-way ANOVA and Dunnett's post-hoc test) (n=3). 
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Figure 1. Annexin A11 mutations identified in ALS patients following stringent filtering of exome sequencing data. 
ANNEXIN	 ANNEXIN	 ANNEXIN	 ANNEXIN	NH2	 COOH	
                                                                                                                
 
Human     SMPPIGLDNVA     GMYPPPGGNPP  YPGYPGSGTVT  PPTQFG--SRG   SNKQRQQILL                  LSQGNRDESTN 
Macaque   SMPPIGLDNVA     GMYPPPGGNPS  YPGYPGSGTVT  PPTQFG--SRG   SNKQRQQILL                  LSQGNRDESTN 
Rabbit    SMPPIGLDNVA     GVYPPPGGNPP  YPGYPGSGTVT  PPVQFG--NRG   SNKQRQQILL                  LSQGNRDESTN 
Dog       SMPPIGLDNMA     GMYPPPGGNPP  YPGYLGSGTVT  PPARFG--NRG   SNKQRQQILL                  LSQGNRDESTN 
Rat       SMPPIGLDNVA     GMYPPPGGNPP  YPGYSGSSTIT  PPAQFG--NRG   SNKQRQQILL                  LSQGNRDESTN 
Mouse     SMPPIGLDNVA     GMYPPPGGNPP  YPGYSGSSTIT  PPAQFG--NRG   SNKQRQQILL                  LSQGNRDESTN 
Elephant  SMPPIGLDNVA     GMYPPPGGNPP  YPAYPGSGNVT  PPTQFG--NRG   SNKQRQQILL                  LSQGNRDESTN 
Chicken   NPPPIGLENVA     GGYPPSGGN--  MPSYPG--PTG  SPGAYG--NRG   SNKQRQQIIL                  LSQGNRDESTN 
Xenopus   ---PIGMDNMS     GMYPPPVAGQP  GPSYPSPPSTT  TP-SYGKVKRG   SNKQRQQISL                  LAQGNRDESNN 
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Figure 2. ANXA11 Immunohistochemistry of post mortem tissue from D40G sporadic patient
(D)		D		A		 B		 C		D40G D40G D40G D40G 
(G) H  E  F  G  
TDP43 Annexin A11 Annexin A11 Annexin A11 
Annexin A11 Annexin A11 Annexin A11  
L  I  J  K  
H  
Annexin A11 
Annexin A11 pTDP43 Annexin A11 Ubiquitin Annexin A11 pTDP43 
N  O  P  
D40G D40G SALS C9ORF72 Spinal Cord 
K  
Annexin A11 Annexin A11 
I  C9ORF72 F Cortex FTLD-TDP43 
Annexin A11   
L  AD 
Annexin A11 
M  Control 
Annexin A11 
SOD1 J  
A WT G38R D40G R235Q
B C ****
**
Figure 3. Functional Annexin A11 studies in mouse Primary Motor Neurons and HEK cells
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Figure 4. R235Q aggregates sequester WT Annexin A11
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Figure 5. Calcyclin analysis: in-vitro binding assays with mutant ANXA11 constructs and staining of post-mortem tissue. 
			
		
		
Supplementary Figure 1. The Annexin A11 p.D40G mutation shares a common haplotype comprised of 4 exonic SNPs and 2 microsatellites. 
Genotyping of 5 polymorphic microsatellites spanning the ANXA11 locus identified the 7.1MB maximal recombination region between microsatellites 
22xTG and 24xAG (marked in red). The 2.5Mb minimal common region specific to all UK affected ALS D40G patients (4 FALS and 1 sporadic ALS 
case) was defined by two microsatellites (21xAC and 25xAT) and 4 exonic SNPs (rs41291392, rs17617713, rs72821609 and rs72805713), ie. 309-T-G-
T-G-250. Genotyping of an unaffected spouse (Generation III-18) and two unaffected D40G carriers  (Generation IV-12 and IV-13) from Family 2 (Figure 
1C) determined haplotype phase. 
					
		
				
Supplementary Figure 2. Haplotype gene map of the ANXA11 D40G locus. The maximal haplotype region (~7.1MB) is defined by the outer limit of 
recombination at the two flanking microsatellites 24xAG and 22xTG (pink region). The minimal common D40G haplotype block (~2.5MB) spans ANXA11 
and is shared by all 5 affected ALS UK cases and two unaffected ALS carriers. Exome sequencing of D40G carriers identified no additional novel or rare 
exonic or splicing variants in the 23 genes located within this maximal locus.  
 
				
		
			
Supplementary Figure 3. Annexin A11 western blot of lysates made from post-mortem tissue of the sporadic patient harbouring the p.D40G 
mutation and control individuals. Western blotting of lysates made from frontal cortex tissue of the sporadic patient harbouring the D40G mutation, 
using a polyclonal Rabbit Annexin A11 antibody, yields a specific single band at ~55kDA. There was no difference in Annexin A11 expression due to the 
D40G mutation compared to lysates made from three control individuals. 
 
			
Supplementary Figure 4. R235Q ANXA11-GFP co-localises with ubiquitin and p62 in HEK cells. (i) Cells were transfected with ANXA11-GFPR235Q 
for 48hrs, fixed and stained with the following antibodies by immuno-cytohistochemistry (ICC) (A) mouse GFP - green. (B) ANXA11 Polyclonal rabbit 
Antibody (Proteintech) - red. (C) Merge of A, B and DAPI blue nuclear staining, showing specificity of ANXA11 specific antibody, (D) mouse GFP - 
green. (E) Rabbit K-48 Ubiquitin - red. (F) Merge of D, E and DAPI. (G) mGFP - green. (H) Rabbit p62 - red. (I) Merge of G, H and DAPI blue nuclear 
staining (ii) Confirmation of specificity of endogenous Rabbit ANXA11 antibody in ICC (as used in 4(i) A-C) for GFP and HA tagged ANXA11 constructs 
by Western blot. 
		
	
Supplementary Figure 5. Modelling of Annexin A11 identifies two amphipathic helices in the N-terminus of Annexin A11 that overlap the 
G38 and D40 residues. (A) Jpred secondary structure prediction of the N-terminus (residues 1-270) using a multiple alignment of 30 mammalian 
orthologue sequences identified two alpha helices, indicated in red (residues 40-44 and 51-59). Green represents potential beta strands. Known 
annexin domains start at ~205 residues. The locations of the G38 and D40 residues are indicated in the first helix. (B) Protein structure of Annexin A1 
(pdb:1hm6) in the presence of calcium, with the annexin domain alpha helices in red and the N-terminal helices in magenta. (C) Jpred also predicts 
the N-terminus of Annexin A1 to possess two alpha helices (residues 3-13 and 19-25). (D) The Jnetpred consensus (top row) predicts that both the 
G38R and the D40G variants abolish the first alpha helix. 	
		
Supplementary Figure 6. Twenty two ExAC polymorphisms spanning the D40 locus do not disrupt the formation of amphipathic helices. 
Secondary structure predictions on the N-terminus of Annexin 11 show that only the ALS-linked mutations G38R & D40G completely abolish the 
formation of the first alpha helix. None of the 22 ExAC variants flanking this region, including D40H, have the same effect.  Secondary structures 
were derived from Jpred4 consensus, performed on a multiple alignment of 30 mammalian orthologues.		
			
		 	
				
Supplementary Figure 7. Rare and common ANXA11 polymorphisms do not disrupt calcyclin binding compared to ALS specific variants. 
Immunoprecipitation (IP) of FLAG-calcyclin from mixed lysates of HEK cells expressing GFP-fused proteins (as indicated) in the presence of 
calcium show similar binding affinities for the P8L, the D40H, the R191Q and the R230C to that of wild-type (WT) when probed for GFP (n=3). The 
top panel shows GFP intensities of input and pulldown fractions, with IgG heavy (*) and light chains (**) indicated. The bottom panel illustrates 
input and IP levels of FLAG-calcyclin. 	
						
												 					
Supplementary Figure 8. N-terminal Annexin A11 mutations do not alter binding of Sorcin and ALG2. (A) Immunoprecipitation (IP) of FLAG-
Sorcin from mixed lysates of HEK cells transfected with ANXA11-GFPWT+G38R+D40G+G189E+R235Q activated with calcium show no difference in binding 
between ANXA11 WT and mutants when probed for GFP. (B) The same was seen when IP was conducted with ALG2-sorcin. (n=3). The top panel 
shows GFP intensities of input and pulldown fractions, with IgG heavy and light chains indicated. The bottom panel for both (A) and (B) illustrates 
input and IP levels of FLAG-sorcin or FLAG-ALG2 respectively. 	
	
Figure	Legends	Supplementary	Tables	
	
Supplementary	Table	1.	Novel	variants	shared	between	all	members	of	each	Familial	ALS	family.	Combined	exome	coverage	and	number	of	shared	novel	protein-altering	variants	for	the	50	families	in	our	FALS	cohort.	*The	estimated	proportion	of	the	genome	shared	by	all	exome	sequenced	cases	of	each	family	was	inferred	from	patient	records	or,	when	these	were	not	available,	calculated	by	Identity-By-Descent	analysis	performed	in	PLINK.		
Supplementary	Table	2.	Novel	variants	shared	between	ANXA11	D40G	Families.	Filtering	reduced	the	numbers	of	novel	protein-altering	variants	in	families	1	and	2	to	6	and	8	candidates,	respectively.			
Supplementary	 Table	 3.	 Homogeneity	 of	 the	 FALS	 cohort	 and	 ExAC	 Non-Finnish	 Europeans.	 *An	 estimate	 of	 intranational	 genetic	homogeneity,	calculated	as	the	average	number	of	Identity-By-Descent	blocks	shared	between	two	unrelated	individuals	[31].	This	indicates	that	the	most	prevalent	population	in	ExAC,	the	Swedish,	are	also	the	most	homogeneous	and	are	therefore	likely	to	share	more	rare	variants	than	the	other	European	nationalities	present	in	either	cohort.			
Supplementary	Table	4.	Primer	sequences	used	in	ANXA11	D40G	haplotype	study	and	for	Sanger	sequencing	of	ANXA11	exons.	*Primers	FAM	labeled.	Genomic	locations	are	according	to	build	hg19	co-ordinates.		
Supplementary	Table	5.	Exon	coverage	data	of	genes	within	the	minimal	D40G	haplotype	region.	Exome	sequencing	data	achieved	a	read	depth	>=10	across	the	minimal	haplotype	region	for	>95%		of	the	coding	bases	in	Family	1,	>85%	in	Family	2	and	>70%	for	the	isolated	index	case.	97.9%	of	the	bases	were	adequately	covered	by	at	least	one	sample,	making	the	existence	of	an	undetected,	shared,	coding	variant	highly	unlikely.	
	
Supplementary	Table	6.	All	variants	found	within	ANXA11	in	FALS	and	SALS.	Frequencies	for	each	variant	were	assessed	in	dbSNP144,	ESP,	ExAC,	1000genomes,	UK10K,	and	ALSdb	(www.alsdb.org).	An	additional	909	UK	and	3596	Italian	exome	controls	were	used	to	 further	assess	frequencies	for	the	p.G38R,	D40G,	P108L,	G175R,	G189E,	R235Q	and	R346C	variants.	The	protein-altering	variants	D40G,	P108L,	G175R	&	R346C	are	 unique	 to	 ALS	 cases.	 Pathogenicity	 predictions	 are	 included	 from	 20	 different	 algorithms,	 obtained	 from	 Annovar	(annovar.openbioinformatics.org).	P108L	did	not	segregate	in	an	affected	sibling	therefore	is	deemed	to	be	a	private	polymorphism.			
Supplementary	Table	7.	Clinical	details	of	patients	with	ANXA11	mutations.	Most	patients	with	N-terminal	mutations	have	late	disease	onset	(average	of	72years).	Patients	carrying	a	D40G	mutation	have	predominantly	bulbar	onset.	There	was	a	distinct	absence	of	FTD	symptoms	in	all	
ANXA11	carriers.	*No	clinical	information	was	available	for	the	affected	sibling	of	Patient	8	that	carried	the	novel	p.G175R	variant.		
